Biotech company Moderna said Monday that preliminary analysis of its Phase 3 trial shows its Covid-19 vaccine is 94.5 percent effective in preventing infection, hoping for another success in several weeks.
Pharmaceutical giant Pfizer said preliminary analysis showed its vaccine candidate was more than 90 percent effective.
Moderna also said that its vaccine does not require ultra-cold storage, unlike the candidate declared by Pfizer, whose temperature is stored at minus 70 degrees Celsius (-94 Fahrenheit) or below, how to effectively deliver the vaccine to billions of people. It eases the worries about it. People from all over the world.
Professor Trudy Lange, director of the Oxford University’s Global Health Network, called Modern’s announcement “really good news.”
The company said that in its Phase 3 trial, U.S. Has more than 30,000 participants, including more than 65 people at risk and people from color communities.
“These preliminary results indicate that the protected group had representation from different age groups and different communities.” “This is really encouraging and further demonstrates that the vaccine for covid is a real possibility and that having more than one supplier will help ensure better and more uniform global availability.”
The announcement is expected to end the coronavirus epidemic that has killed more than 1.3 million people worldwide and spread global economic unrest. The news also comes that the United States has surpassed more than 110 million Kovid-19 cases and the number of cases in Europe is steadily rising.
“I think this is a great step where we want to stay in control of this outbreak,” said Dr. Naidu, director of the National Institute of Allergy and Infectious Diseases.
The company said the analysis showed no significant safety concerns, and the vaccine was generally well tolerated.
His interim analysis was based on 95 infections in the trial participants who received either a placebo or a vaccine. Of those, only five were infected with the vaccine.
Moderna said its vaccine is expected to remain stable for 30 days at a standard refrigerator temperature of 2 to 8 degrees Celsius (36 to 46 Fahrenheit), higher than the previous 7-day estimate. The vaccine can withstand temperatures of -20 degrees Celsius (-4 Fahrenheit) for up to six months and room temperature for up to 24 hours, the company said.
Download the NBC News app for the latest news on coronavirus
These temperatures are commonly found in readily available pharmaceutical freezers and refrigerators that will enable easy distribution in the United States and other parts of the world, the company said in a statement.
Fawcett predicted that by the end of December, doses of the vaccine from both Moderna and Pfizer would be available to individuals “in the high-risk category.”
But he warned that in order to double public health measures, including wearing face masks and social distance, “the way to help is to give us more encouragement.”
Moderna plans to apply for emergency use authorization with the Food and Drug Administration next week.
By the end of the year, it expects 20 million doses of the vaccine to be given in the US and will produce 500 million to 1 billion doses globally next year.
